Global Injectable Manufacturer with a focus on CDMO business model

What we do?

We are focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. We are present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings. Our production of complex generic injectables are powered by our deep R&D expertise and robust manufacturing capabilities.


Our four best-in-class, cGMP-compliant formulation manufacturing facilities manufacture a wide range of injectables using aseptic filling or terminal sterilization, as applicable.


Our 4 API facilities have in-house manufacturing capabilities that help us integrate backwards and develop products that many others may overlook because of API supply uncertainty.


Our two state-of-the-art R&D divisions in Hyderabad is staffed by nearly 300 qualified scientists. The labs engage in Formulation Development, Analytical Method Development, API Process Development and Stability Studies.

Who are we?

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the pharmaceutical research and development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We have a professional management team and one of our Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.

Know More

Investor Centre

Our scientifically curated strategy is key to
delivering long-term value for employees, shareholders and investors.

Investor Resources

Q1 FY23 Investor presentation

Q2 FY23 Investor presentation

Q3 FY23 Investor presentation

View All

Annual Report 2021-22 (Double Page)

Annual Report 2021-22 (Single Page)

Annual Return 2021-22

View All

Q1 FY23 Unaudited Financial Results - Consolidated

Q1 FY23 Unaudited Financial Results - Standalone

Q2 FY23 Unaudited Financial Results - Consolidated

Q2 FY23 Unaudited Financial Results - Standalone

Q3 FY23 Unaudited Financial Results - Consolidated

Q3 FY23 Unaudited Financial Results - Standalone

View All

Shareholding Pattern as on December 31, 2022

Memorandum & Articles of Association

Statement of Deviation or Variation for Q2FY23.

Monitoring Agency Report Q4FY22

View All
Latest earnings news release

CSR Activity

Our responsibility towards people, patients, communities and the natural environment override our business endeavours.

CSR Videos & Images

The CSR Journal Excellence Award 2nd Runner up
csr excellence award photo